U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H22N2O
Molecular Weight 246.348
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Sophocarpine

SMILES

[H][C@]12CCCN3CCC[C@]([H])([C@@]4([H])CC=CC(=O)N4C1)[C@]23[H]

InChI

InChIKey=AAGFPTSOPGCENQ-JLNYLFASSA-N
InChI=1S/C15H22N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h1,7,11-13,15H,2-6,8-10H2/t11-,12+,13+,15-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H22N2O
Molecular Weight 246.348
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: doi: 10.1248/cpb.13.482
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/24587659 | https://www.ncbi.nlm.nih.gov/pubmed/23395669 | https://www.ncbi.nlm.nih.gov/pubmed/18379053

Sophocarpine is a dehydrogenation derivative of the bis-quinolizidine alkaloid matrine. Sophocarpine is also an active component in sophora alkaloids, which possess a variety of pharmacological effects such as anti-inflammation, immunity regulation, antivirus, and anti-tumor actions. Sophocarpine is able to block HERG K+ channel. It is Na+ channel inward current inhibitor. It activates the AMPK signaling pathway and inhibits the TLR4-downstream pathway.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Mechanism of sophocarpine in treating experimental colitis in mice].
2015 Aug
Inhibition of Sophocarpine on Poly I: C/D-GalN-Induced Immunological Liver Injury in Mice.
2016
RETRACTED: Sophocarpine displays anti-inflammatory effect via inhibiting TLR4 and TLR4 downstream pathways on LPS-induced mastitis in the mammary gland of mice.
2016 Jun
Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine.
2016 Jun 28
Patents

Sample Use Guides

Rat: 20 mg/kg once a day
Route of Administration: Intraperitoneal
In the presence of ATX II, SOP (20, 40, and 80 mM) reversed the increased INa.L in a concentration-dependent manner.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:22:08 GMT 2023
Edited
by admin
on Sat Dec 16 09:22:08 GMT 2023
Record UNII
X9X8U6P2NP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Sophocarpine
Common Name English
(-)-Sophocarpine
Common Name English
(7aS,13aR,13bR,13cS)-2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3′,2′,1′-ij][1,6]naphthyridin-10-one
Systematic Name English
1H,5H,10H-Dipyrido[2,1-f:3′,2′,1′-ij][1,6]naphthyridin-10-one, 2,3,6,7,7a,8,13,13a,13b,13c-decahydro-, (7aS,13aR,13bR,13cS)-
Systematic Name English
13,14-Dehydromatrine
Common Name English
Matridin-15-one, 13,14-didehydro-
Common Name English
13,14-Didehydromatrine
Common Name English
Code System Code Type Description
FDA UNII
X9X8U6P2NP
Created by admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
PRIMARY
EPA CompTox
DTXSID90215126
Created by admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
PRIMARY
PUBCHEM
115269
Created by admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
PRIMARY
CAS
6483-15-4
Created by admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
PRIMARY